Monoclonal antibodies inhibitors of the epidermal growth factor receptor (iEGFR) represent a therapeutic option with proven efficacy for patients with metastatic CRC and wild-type KRAS and NRAS genes. Here, EGFR is linked to colorectal carcinoma.